Candel Therapeutics (NASDAQ: CADL) has announced the appointment of Mark Sims as its chief commercial officer (CCO), effective July 6, 2026.
Mr. Sims will lead Candel’s commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) in intermediate- to high-risk localized prostate cancer.
In a statement, Paul Peter Tak, MD, PhD, FMedSci, president and CEO of Candel, commented, “The appointment of Mark Sims represents another important step in Candel’s evolution toward becoming a potential commercial-stage oncology company. With positive phase 3 clinical trial data, the FDA’s Regenerative Medicine Advanced Therapy designation, a planned BLA submission for aglatimagene in the fourth quarter of 2026, and preparation for a potential commercial launch already underway, we are building the capabilities required to bring aglatimagene, if approved, to patients as efficiently as possible.”
Dr. Tak added, “We believe that intermediate- to high-risk localized prostate cancer represents a large and well-defined market opportunity, with approximately 65,000 patients diagnosed annually in the United States who are candidates for radiotherapy-based treatment approaches with curative intent. Mr. Sims has led and scaled some of oncology’s most significant franchises, and we believe his deep experience bringing innovative therapies to market will be instrumental to making aglatimagene, if approved, available to patients.”
